Author:
Matsumoto Misako,Azuma Masahiro,Seya Tsukasa
Reference56 articles.
1. Akazawa T, Ebihara T, Okuno M, Okuda Y, Shingai M, Tsujimura K, Takahashi T, Ikawa M, Okabe M, Inoue N, Okamoto-Tanaka M, Ishizaki H, Miyoshi J, Matsumoto M, Seya T (2007) Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci U S A 104(1):252–257
2. Azuma I, Ribi EE, Meyer TJ, Zbar B (1974) Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. J Natl Cancer Inst 52(1):95–101
3. Azuma M, Sawahata R, Akao Y, Ebihara T, Yamazaki S, Matsumoto M, Hashimoto M, Fukase K, Fujimoto Y, Seya T (2010) The peptide sequence of diacyl lipopeptides determines dendritic cell TLR2-mediated NK activation. PLoS One 5(9):e12550
4. Azuma M, Ebihara T, Oshiumi H, Matsumoto M, Seya T (2012) Cross-priming for antitumor CTL induced by soluble Ag + polyI:C depends on the TICAM-1 pathway in mouse CD11c(+)/CD8α(+) dendritic cells. Oncoimmunology 1(5):581–592
5. Azuma M, Takeda Y, Okada S, Nakajima H, Sugiyama H, Ebihara T, Oshiumi H, Matsumoto M, Seya T (2015) BATF3 in CD8a+DC sustains TLR3-derived IL-12 induction and CD11c+ anti-tumor T cell responses during antigen + poly(I:C) treatment. Cancer Res Immunol (submitted)